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E-mail address: lkotula@nybloodcenter.org (L. KotMacropinocytosis is regulated by Abl kinase via an unknown mechanism. We previously demon-
strated that Abl kinase activity is, itself, regulated by Abi1 subsequent to Abl kinase phosphorylation
of Abi1 tyrosine 213 (pY213) [1]. Here we show that blocking phosphorylation of Y213 abrogated the
ability of Abl to regulate macropinocytosis, implicating Abi1 pY213 as a key regulator of macropin-
ocytosis. Results from screening the human SH2 domain library and mapping the interaction site
between Abi1 and the p85 regulatory domain of PI-3 kinase, coupled with data from cells transfec-
ted with loss-of-function p85 mutants, support the hypothesis that macropinocytosis is regulated by
interactions between Abi1 pY213 and the C-terminal SH2 domain of p85—thereby linking Abl kinase
signaling to p85-dependent regulation of macropinocytosis.
Structured summary:
MINT-7908602: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to SHIP2 (uniprotkb:O15357) by array technol-
ogy (MI:0008)
MINT-7908362: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to Emt (uniprotkb:Q08881) by array technology
(MI:0008)
MINT-7908235: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to Lyn (uniprotkb:P07948) by array technology
(MI:0008)
MINT-7908075: Abi1 (uniprotkb:Q8IZP0)binds (MI:0407) to Fgr (uniprotkb:P09769) by array technology
(MI:0008)
MINT-7908330, MINT-7908522: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to Vav1 (uniprotkb:P15498) by
array technology (MI:0008)
MINT-7907962: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to Fyn (uniprotkb:P06241) by array technology
(MI:0008)
MINT-7908203: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to Src (uniprotkb:P12931) by array technology
(MI:0008)
MINT-7908570: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to SHP-2 (uniprotkb:P35235) by array technol-
ogy (MI:0008)
MINT-7908187, MINT-7908586: Abi1(uniprotkb:Q8IZP0) binds (MI:0407) to Gap (uniprotkb:P20936) by
array technology (MI:0008)
MINT-7907981, MINT-7907995: Abi1 (uniprotkb:Q8IZP0) physically interacts (MI:0915) with p85a (uni-
protkb:P26450) by anti tag coimmunoprecipitation (MI:0007)
MINT-7908251: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to PLCG1 (uniprotkb:P19174) by array technol-
ogy (MI:0008)
MINT-7908346: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to Grb2 (uniprotkb:P62993) by array technol-
ogy (MI:0008)
MINT-7907945: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to Abl (uniprotkb:P00519) by array technology
(MI:0008)chemical Societies. Published by Elsevier B.V. All rights reserved.
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3280 P.M. Dubielecka et al. / FEBS Letters 584 (2010) 3279–3286MINT-7908474: Abi1 (uniprotkb:Q8IZP0)binds (MI:0407) to p85b (uniprotkb:O00459) by array technology
(MI:0008)
MINT-7908107: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to Hck (uniprotkb:P08631) by array technology
(MI:0008)
MINT-7908011: p85a (uniprotkb:P26450) physically interacts (MI:0915) with Abi1 (uniprotkb:Q8IZP0) by
pull down (MI:0096)
MINT-7908155: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to FynT (uniprotkb:P06241-2) by array technol-
ogy (MI:0008)
MINT-7908283, MINT-7908490: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to p55g (uniprotkb:Q92569) by
array technology (MI:0008)
MINT-7907929, MINT-7907815, MINT-7907832, MINT-7907865, MINT-7907897, MINT-7907913, MINT-
7907881, MINT-7907848: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to p85a (uniprotkb:P27986) by array
technology (MI:0008)
MINT-7908059: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to Frk (uniprotkb:P42685) by array technology
(MI:0008)
MINT-7908378: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to CblC (uniprotkb:Q9ULV8) by array technology
(MI:0008)
MINT-7908618: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to CblA (uniprotkb:B5MC15) by array technology
(MI:0008)
MINT-7908139, MINT-7908538: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) toNap4 (uniprotkb:O14512) by
array technology (MI:0008)
MINT-7908426: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to CblB (uniprotkb:Q13191) by array technology
(MI:0008)
MINT-7908506: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to Crk (uniprotkb:P46108) by array technology
(MI:0008)
MINT-7908554: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) tomAbl (uniprotkb:P00520) by array technology
(MI:0008)
MINT-7908043, MINT-7908394: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to Vav2 (uniprotkb:P52735) by
array technology (MI:0008)
MINT-7908458: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) tomSck/ShcB (uniprotkb:Q8BMC3) byarray tech-
nology (MI:0008)
MINT-7908091: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to Yes (uniprotkb:P07947) by array technology
(MI:0008)
MINT-7908219: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to Src (uniprotkb:P00523) by array technology
(MI:0008)
MINT-7908123: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to Fer (uniprotkb:P16591) by array technology
(MI:0008)
MINT-7908410: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to CrkL (uniprotkb:P46109) by array technology
(MI:0008)
MINT-7908314, MINT-7908442: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to Arg (uniprotkb:P42684) by
array technology (MI:0008)
MINT-7908299: Abi1 (uniprotkb:Q8IZP0)binds (MI:0407) toPLCG1 (uniprotkb:P10686)byarray technology
(MI:0008)
MINT-7908171: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to Fes (uniprotkb:P07332) by array technology
(MI:0008)
MINT-7908027: Abi1 (uniprotkb:Q8IZP0) binds (MI:0407) to Lck (uniprotkb:P06239) by array technology
(MI:0008)
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Macropinocytosis is an actin polymerization-dependent cellu-
lar process responsible for extracellular ﬂuid and macromolecule
uptake; however, the details of the mechanisms regulating macr-
opinocytosis remain unclear [2,3]. In mammalian cells macropin-
ocytosis is thought to be regulated by multiple pathways, which
include several actin polymerization regulatory complexes, and
involves receptor and non-receptor tyrosine kinases [4,5]. Abl ki-
nases (Abl and Arg) are unique among cytoplasmic tyrosine ki-
nases in their capacity to directly bind actin and to regulate
actin polymerization [6,7]. Abl kinase activity is regulated by
Abi1 [1,8]. The fact that overexpression of Abi1 inhibits macropin-
ocytic uptake of ﬂuorescent, water-soluble markers in NIH 3T3
[9] together with recent reports indicating that the anti-Abl drug
Gleevec (STI-571) inhibits macropinocytic uptake of pathogenicbacteria [10,11], suggests the possibility that Abl tyrosine kinase
activity is a key regulatory component of macropinocytosis.
Moreover, expression of isoform 2 of Abi1, which inhibits Abl
tyrosine activity [1], also reduces macropinocytic uptake in LNCaP
cells [12].
Abl tyrosine kinase is implicated in regulating phosphotyro-
sine-mediated Abi1 interactions with several actin polymeriza-
tion regulatory complexes [13] including PI-3 kinase [14]. PI-3
kinase involvement in regulating actin dynamics is well estab-
lished [15], but is mostly attributed to the regulatory subunits
of PI-3 kinase [16–18]. Studies have most often pointed to a
critical role of the p85 subunit in formation of actin-rich mem-
brane rufﬂes, which precedes ﬂuid phase uptake into macropin-
ocytic vesicles. PI-3 kinase activity was proposed to play a role
in the closure of immature membrane rufﬂes to produce a mac-
ropinosome [19,20]. Wortmannin, an irreversible, PI-3 kinase
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membrane rufﬂes but not in all cells [21]. We previously dem-
onstrated that wortmannin, and LY294002, a reversible PI-3 ki-
nase inhibitor, inhibit macropinocytic uptake of Alexa Fluor 594
in NIH 3T3 cells [9]. Recent studies supporting the importance
of PI-3 kinase and PIP signaling in the process [5] suggest that
macropinosome maturation involves subsequent phosphatidylin-
ositol 4,5-biphosphate-, and phosphatidylinositol 3,4,5-triphos-
phate-enriched stages [22,23].
Membrane rufﬂing [24] and enhanced macropinocytosis has
been linked to enhanced Rac1 activation following PDGF stimula-
tion [25]. In this regard, the growth factor-dependent activation
of Rac1 occurs downstream of p85 interaction with the trimeric
complex containing Abi1, Eps8, and Sos1 [14], which is mediated
by the p85 N-terminal SH2 domain and Abi1 phosphotyrosine
pY407 [14]. We hypothesized that the functional phosphotyro-
sine-dependent interaction of p85 with Abi1 involves Abi1 isoform
2, which binds active Rac1 [12]. Here we demonstrate that Abi1
isoform 2 is capable of multiple interactions with p85, but Abi1
pY213 and the p85 C-terminal SH2 domain speciﬁcally cooperate
through a high afﬁnity interaction to inhibit macropinocytic up-
take in LNCaP cells.2. Materials and methods
2.1. Cell lines
LNCaP cells stably expressing HA-tagged wild type Abi1 or Abil
Y213F mutant [1] of isoform 2 (NM_001012750.1) [26] were
grown in RPMI 1640 with 10 mM Hepes, 1 mM sodium pyruvate,
and 2 mM glutamax (Invitrogen, Carlsbad, CA) supplemented with
10% fetal bovine serum (Hyclone, Logan, UT).
2.2. Antibodies and reagents
Alexa Fluor 647 hydrazide, tris (triethylammonium) salt and
Lipofectamine 2000 Transfection Reagent were from Invitrogen
(Carlsbad, CA). PDGF BB (cat # 3201), wortmannin and latrunculin
A were from Sigma–Aldrich (St. Louis, MO). Glutathione Sepharose
4B was from Amersham Biosciences (Piscataway, NJ). Imatinib
mesylate (STI-571) was from Biofﬁn GmbH, Germany. Horseradish
peroxidase-labeled goat anti-rabbit IgG, goat anti-mouse IgG and
Protein G plus agarose were from Thermo Fisher Scientiﬁc
(Worcester, MA). Monoclonal antibody to HA and His6 epitopes
were from Roche Diagnostic Corporation (Indianapolis, IN). Poly-
clonal anti-GFP antibody was from Invitrogen. Rabbit antibody to
p85 (clone 19H8) was from Cell Signaling Technology (Danvers,
MA). Protease inhibitor cocktail set I and set III were from EMD
Chemicals Inc. (Gibbstown, NJ).
2.3. p85 expression plasmids
The loss-of-function p85 SH2 domain mutations, R358L (within
the N-terminal SH2 domain), or R649L (within the C-terminal SH2
domain) [27], were introduced into the full-length p85-GFP
(mouse), using Quick Change XL site directed mutagenesis kit
(Stratagene, La Jolla, CA).
2.4. Recombinant Abi1 puriﬁcation and afﬁnity binding assay was
performed as described [12]
Cells were transfected with wild type p85 or its mutants and
subjected to immunoprecipitation and evaluation by Western
blotting as described [9,26] except that NuPAGE gels (Invitrogen,
Carlsbad, CA) were used.2.5. Flow cytometric uptake assay of Alexa Fluor 647
Assay of cellular uptake of Alexa Fluor 647 was performed
essentially as described [9], but was quantiﬁed by ﬂow cytometry
[12]. For uptake assays, following seeding into 12-well for 24 h and
washing, cells were preincubated with 0.2 lM wortmannin or
2 lM imatinib mesylate (STI-571) (30 min), and incubated in the
same medium with or without 10 ng/ml PDGF for 2 h along with
Alexa Fluor 647 hydrazide (25 lM). In similar experiments in
which cells were treated with 0.2 lM latrunculin A, PDGF was
not added. Following washing with PBS (37 C) harvested cells
(0.25% trypsin, 1 min) were subjected to cytoﬂuorimetric analysis
(BD FACS Canto, Becton Dickinson, San Jose, CA) in which the rela-
tive cellular content of Alexa Fluor 647 was measured by ﬂuores-
cence intensity of the internalized dye in live cells. Intensity was
obtained as a mean per cell value for 104 cells in each measure-
ment. In transfection experiments with GFP tagged proteins, a po-
sitive Alexa Fluor 647 signal was evaluated only in GFP positive
cells. For immunoprecipitations, cells were incubated with
100 ng/ml PDGF for 5 min.
3. Reverse-phase SH2 domain binding assay [28,29] is described
in Supplementary data
3.1. Immunoﬂuorescence microscopy
For microscopic observations, cells were grown on glass bottom
dishes (MatTek Corporation, Ashland, MA), treated as for ﬂow cyto-
metric uptake, and ﬁxed with warm 4% paraformaldehyde for
20 min. Representative images were collected using a Zeiss Meta
510 Confocal Laser Scanning Microscope with a 100 NA oil objec-
tive. Images were processed using Adobe Photoshop CS3.
3.2. Data analysis
The signiﬁcance of the data was analyzed using One Factor An-
ova. The Holm-Sidak test was used for comparison versus a control
group. Differences with P value <0.05 were considered signiﬁcant
(marked as a star in ﬁgures). Error bars represent the standard er-
ror of the mean (S.E.M.).
4. Results
4.1. High afﬁnity interaction between Abi1 phosphopeptide pY213 and
p85 regulatory subunit of PI-3 kinase
We previously demonstrated that tyrosine 213 (Y213) of Abi1
isoform 2 was an Abl kinase-dependent and Gleevec-sensitive
phosphorylation site [1]. We hypothesized that after being phos-
phorylated at pY213, Abi1 would bind a downstream cellular li-
gand. We therefore searched for Abi1 pY213 interacting proteins
by screening the genome-wide human GST-SH2 domain library
as described [28]. As a comparison peptide we used an Abi1-de-
rived peptide containing pY421 (Fig. 1A). Among proteins that
bound with the highest afﬁnity to Abi1 pY213 was a recombinant
polypeptide containing the N- and C-terminal SH2 domains of the
p85 regulatory subunit of PI-3 kinase (Fig. 1B) (Supplementary
Fig. S1). Unphosphorylated peptide controls demonstrated no
appreciable afﬁnity in the genome wide screening (Supplementary
Figs. S1 and S3). In addition, consistent with our previous observa-
tions, pY213 bound with relatively high afﬁnity (but lower than to
p85) to the Abl SH2 domain [1]. In contrast, pY421, showed high
afﬁnity binding to Fyn SH2 domain, weak binding to p85 and no
binding to the Abl SH2 domain (Fig. 1). These data suggested that
the Abi1 pY213 signaling pathway involved Abi1 interaction with
p85 subsequent to Abi1 phosphorylation by Abl kinase.
Fig. 1. Identiﬁcation of high afﬁnity interactions of Abi1 with p85 regulatory subunit of PI-3 kinase through genome-wide SH2 domain phosphotyrosine peptide screening.
(A) Sequence and location of Abi1 phosphopeptides used in SH2 domain screening. Peptide sequences are listed above speciﬁc exons of the Abi1 schematic diagram; amino
acid residue numbering is according to the full-length Abi1 (isoform 1 [26]). Isoform 2, lacking exon 8, was used in the study. (B) Identiﬁcation of high afﬁnity Abi1–pY213
interaction with p85. Synthesized phospho-peptides corresponding to pY213 and pY421 of Abi1 and controls were immobilized on a membrane in multiple duplicate arrays
as shown on top. The assay positive control was a cocktail of lysates prepared from pervanadate-treated cells, and negative control a lysates with tyrosine phosphatase-
treated [28]. An anti-phosphotyrosine blot is shown as a loading control. Labeled SH2 domains of Abl, p85 (containing both N-terminal and C-terminal SH2 domains), and Fyn
were added into separate wells at indicated concentrations, and SH2 binding was detected by chemiluminescence. Quantiﬁed data were plotted against the SH2 probe
concentration and equilibrium dissociation constants (Kd) values were determined by curve ﬁtting. Afﬁnities for some SH2–peptide interactions were not obtainable due to
weak binding/low signal (undeﬁned). For entire screening results including non-phosphotyrosine peptide controls see Supplementary Fig. S1.
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Fig. 2. Abi1 regulates cellular uptake of Alexa Fluor 647 through tyrosine 213. (A)
Effect of actin polymerization, Abl and PI-3 kinase inhibitors on macropinocytic
uptake. Representative confocal images from merged DIC and Alexa Fluor 647
(green) channels of LNCaP cells expressing wild type (Abi1wt) or Y213F mutation
(Abi1Y213F). Cells were incubated with Alexa Fluor 647 for 2-hr following
treatment with indicated agents as described in Section 2. (B) Expression of Abi1
Y213F enhances cellular uptake of Alexa Fluor 647 and reduces sensitivity to
inhibitors (wortmannin and STI-571). Measurements of Alexa Fluor 647 uptake
were performed by ﬂow cytometric assay in cell lines expressing wild type or Y213F
mutant of Abi1 in the presence of PDGF and following treatment with indicated
agents as described in Section 2. Measurements were performed in triplicate, n = 3,
error bars ± S.E.M. (C) p85 C-SH2 domain mutation cooperates with Abi1 Y213F to
enhance uptake of Alexa Fluor 647. LNCaP cells expressing wild type or Abi1 Y213F
mutant of isoform 2 cells were co-transfected with p85 or p85-SH2 domain
mutants as indicated. Abi1 isoform 2 inhibits macropinocytic uptake in comparison
to Mock cells as previously observed [12]. Measurements were obtained in the
presence of PDGF as described in Section 2. Measurements were performed in
triplicate, n = 3, error bars ± S.E.M.
Fig. 2 (continued)
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Fluor 647
As indicated in Introduction, Abi1 and Abl kinase functions have
been linked to regulation of macropinocytosis. The data that Ablkinase activity is regulated through Abi1 pY213 [1], provided
rationale to determine the role of Y213 in macropinocytosis in
the context of Abl kinase regulation. To do so we examined macr-
opinocytic uptake of Alexa Fluor 647 in cells stably expressing the
Abi1 Y213F substitution. Analysis indicated that cellular uptake of
Alexa Fluor 647 was signiﬁcantly enhanced in cells expressing Abi1
Y213F mutant in comparison to cells expressing wild type recom-
binant Abi1. Although Abi1 Y213F clone demonstrated PDGF re-
sponse, the ﬁnding that Y213F mutation led to constitutive
enhancement of Alexa Fluor 647 uptake (Fig. 2A and B) suggested
that phosphorylation of Abi1 on pY213 negatively regulated macr-
opinocytosis. Consistent with our recent ﬁndings, the ﬂuorescent
dye accumulated in large cell extensions [12], which are increased
in numbers in cells expressing Abi1 Y213F (Supplementary
Fig. S2).
4.3. Y213F mutation changes sensitivity of Alexa Fluor 647 uptake to
Abl kinase and PI-3 kinase inhibitors
Involvement of p85 regulatory subunit of PI-3 kinase and Abl ki-
nase activity prompted the use of speciﬁc inhibitors of the kinases
to compare the uptake of Alexa Fluor 647 between LNCaP cell lines
overexpressing Abi1 wild type or Y213F mutant. The abilities of
wortmannin or of STI-571 treatment to inhibit macropinocytic
uptake in LNCaP cells carrying the Abi1 Y213F mutation was abol-
ished or reduced, respectively. Both LNCaP cell lines demonstrated
a signiﬁcant decrease in response to Latrunculin A, which is an
actin depolymerization agent (Fig. 2A and B).
Fig. 3. Abi1 pY213 interacts with p85 preferentially through the p85 C-terminal SH2 domain in transfected LNCaP cells. (A) Interaction of Abi1 Y213F mutant with p85 is
reduced by C-SH2 mutation. LNCaP cell lines expressing Abi1 wt or Y213F mutant were transfected with p85 or p85-SH2 domain mutants as indicated. Following
immunoprecipitations using anti-HA antibody, samples were separated on SDS–PAGE gels and transferred as described in Section 2. Membranes were blotted with anti-p85.
Input indicates p85 levels in whole cell lysate; Abi1, levels of Abi1 in immunoprecipitated samples. Numbers within the top panel indicate relative band intensity normalized
to the p85-GFP band with no PDGF. Immunoprecipitations were performed in the presence or absence of PDGF as indicated. (B) Afﬁnities of Abi1 peptides to p85 SH2
domains. Afﬁnity measurements were made using the assay [28] described in Fig. 1B and Section 2. Quantiﬁed data were plotted against the SH2 probe concentration and
equilibrium dissociation constants (Kd) values were determined by curve ﬁtting. Afﬁnities of Abi1 phosphopeptides for the N-terminal (p85a N-SH2) and for the C-terminal
(p85a C-SH2) domain of p85 are listed in table below graphs. Afﬁnity of the pY421 to p85a C-SH2 domain interaction was not obtainable due to low signal (undeﬁned).
Sequence of Abi1 peptides used here are listed in Fig. 1A. (C) Mapping of p85 interaction with recombinant Abi1. (Top) Schematic representation of Abi1 truncated mutants
used for mapping. A total of seven Abi1(His-tagged) constructs were used, each represents a major domain or a region in the Abi1 protein (as indicated). (Bottom) Bacterial
lysates containing p85-GST and Abi1-His proteins were combined and lysed. p85-GST-interacting Abi1 polypeptides were evaluated following elution of the bound fraction
from Glutathione Sepharose 4B column as described (Section 2). Western blotting results of the eluted samples: Abi1 recombinant protein input (anti-His antibody) (top
panel); Abi1 polypeptides binding to p85-GST (anti-His antibody) (middle panel); and GST control (GST antibody) (lower panel). The mapping was done using recombinant
peptides derived from Abi1 isoform 2 (lacking exon 8) and isoform 3 (lacking exon 10) as indicated in fragments. Abi1 contains several domains: T-SNARE, homeobox
homology region (HHR), PXXP sequence-rich region (PXXP RR), Proline-rich and PXXP-rich region and (RPP), and an SH3 domain.
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macropinocytic uptake of Alexa Fluor 647
Our earlier results indicated high afﬁnity interaction of Abi1
pY213 with the p85 fragment containing both the N- and C-termi-
nal SH2 domain. To determine if the up-regulation of macropino-
cytic uptake in cells expressing Abi1 Y213F mutant was
mediated by loss of interaction between Abi1 pY213 and one of
the p85 SH2 domains, as suggested by in vitro binding results with
the mutant peptide Y213F, we analyzed Alexa 647 uptake in LNCaP
cell lines transfected with the full-length p85 containing a loss-of-
function mutation either in the N-terminal SH2 domain, p85 N-
SH2 R356L, or in the C-terminal SH2 domain, p85 C-SH2 R649L
(Fig. 2B). These mutations render p85 SH2 domains incapable of
binding phosphotyrosine-containing ligands [27]. In control cells
(mock transfected), expression of the C-SH2 domain mutant mod-
erately enhanced macropinocytosis compared to cells expressing
wt p85 or the N-SH2 mutant. In cells expressing Abi1 Y213F the
C-SH2 mutant signiﬁcantly enhanced uptake, but had no effect in
cells expressing wt Abi1. Thus, the Y213F substitution resulted in
dependence of uptake on the C-SH2 domain. Mutating the N-SH2
domain had only a moderate effect on reducing uptake in cells
expressing wild type Abi1. In summary, these data indicate that
Abi1 pY213 and p85 C-SH2 domain are important in the context
of full-length proteins to regulate macropinocytic uptake in LNCaP
cells.
4.5. Abi1 pY213 interacts with p85 preferentially through the p85 C-
terminal SH2 domain
To further conﬁrm that the p85-Abi1 association is regulated by
interaction between Abi1 pY213 and the C-SH2 domain, we ana-
lyzed protein complexes immunoprecipitated from LNCaP cell
lines. The results indicated that the interaction between Abi1
Y213F and the full-length p85 was reduced by the C-terminal
SH2 domain mutation to a greater extent than by the N-terminal
SH2 domain mutation (Fig. 3A). These data also suggested that
the interaction between Abi1 and p85 was primarily dependent
on the presence of phosphorylated Abi1 Y213, because pY213 pep-
tide exhibited a high afﬁnity interaction with p85, but there was no
binding of Y213F peptide to p85 in the screening (Supplementary
Fig. S1). The interaction of the full length Abi1 containing Y213F
mutation with p85 was also observed under the non-phosphory-
lating conditions, i.e., without PDGF (Fig. 3A). These data indicated
that although pY213 is important for the interaction between Abi1
and p85, other interaction sites might be present in the complex.
To assess these candidate interactions we established afﬁnities
of Abi1 phosphopeptides to separate p85 SH2 domains in vitro. In
addition to pY213 and pY421, we included pY506, which is an-
other Abl kinase dependent site (Section 2). Afﬁnity measure-
ments indicated that while the isolated N-SH2 of p85 was
capable of high afﬁnity phosphotyrosine-dependent interaction
with all three Abi1-derived peptides, the C-SH2 domain showed
a preference for pY213 and pY506, with no measurable afﬁnity
for pY421 (Fig. 3B; see also Supplementary Fig. S3). Therefore,
we postulated that the full-length Abi1-Y213F mutant might asso-
ciate with p85 N-SH2 R356L through an interaction mediated by
the intact C-SH2 and Abi1 pY506, and with p85 C-SH2R649L
through an interaction mediated by the intact N-SH2 with
pY506 or pY421. These candidate interactions might explain
residual binding between Abi1 Y213F and the p85 mutant under
phosphorylated conditions.
To understand the basis of Abi1–p85 interactions under non-
phosphorylated conditions we analyzed the interaction of the re-
combinant polypeptides. We mapped the binding site of p85 to
an Abi1 proline-rich and PXXP consensus containing fragment, res-idues 390–508 (Fig. 3C). These data raise the possibility that Abi1
Y213F interaction with p85 might be mediated by p85 SH3 domain
(Fig. 3C). These data support the hypothesis that, although Abi1
interacts with p85 through multiple sites, the critical interaction
regulating macropinocytosis uptake involves Abi1 pY213 and the
p85 C-SH2 domain.5. Discussion
In this report we have identiﬁed a critical link between Abl ki-
nase and PI-3 kinase signaling that involves an adaptor function of
Abi1. We demonstrate that Abi1 regulates macropinocytic uptake
through an interaction with the p85 regulatory subunit of PI-3 ki-
nase. The data indicate that Abi1 phosphotyrosine 213 co-operates
with the C-terminal SH2 domain of p85 to inhibit macropinocyto-
sis. We propose that Abi1 pY213 links Abl kinase signaling to p85-
dependent regulation of macropinocytosis.
5.1. Abi1 Y213F mutation enhances macropinocytic uptake through
abnormally regulated interactions with p85
Although p85 is capable of association with Abi1 Y213F, loss of
the interaction with p85 C-SH2 domain seems to be critical for up-
regulating macropinocytosis. Our in vitro binding data indicate
that two candidate interaction sites for p85 N-SH2 domain remain
on Abi1 Y213F, i.e., pY421 and pY506. The latter is also capable of
interacting with p85 C-SH2 domain. These data, together with the
previously identiﬁed interaction of pY407 (numbering according to
[14]) with the N-terminal SH2 domain of p85 [14], provides a ratio-
nale to explain the residual binding of the Y213F mutant under
phosphorylating-conditions. The existence of multiple phospho-
interaction sites on Abi1 suggest a complex mechanism of regula-
tion, possibly involving competition among the phosphorylated
tyrosines of Abi1 for binding to the p85 SH2 domains. We demon-
strated that speciﬁc loss of Abi1 interaction with p85 C-SH2 do-
main, revealed here by Abi1 Y213F mutation, rather than the
complete loss of the Abi1 interaction with p85, is critical for the
regulation of macropinocytosis.
Based on the fact that Abi1 wt but not Abi1 Y213F, mediates a
decrease in uptake in the presence of p85 C-SH2 domain mutation,
we propose that Abi1 pY213 is a downstream mediator of a p85 C-
SH2 domain signal. Our analysis here pertains to Abi1 isoform 2,
which inhibits Abl kinase activity [1] and inhibits macropinocyto-
sis, possibly through cytoplasmic sequestration of active Rac1 [12].
Direct interaction of active Rac1 with Abi1 is isoform-speciﬁc [12],
raising the possibility of isoform-speciﬁc effects of p85–Abi1 inter-
actions on Rac1 activation. Abi1 isoform-speciﬁc patterns of tyro-
sine phosphorylation, if different, might also contribute to the
regulation of Abi1 interactions with p85. In this regard, more com-
prehensive analysis of tyrosine phosphorylation site mutants
including tyrosine Y421 and Y506, in the context of Abi1 isoforms,
will lead to better understanding p85-dependent regulation of
macropinocytosis. In Abi1 isoform 2, tyrosine Y213 appears to play
a critical role, as shown by the fact that introduction of Y213F
mutation produces a similar effect on macropinocytosis as does
siRNA-mediated downregulation of isoform 2, i.e., increased
uptake [12].
Abi1 Y213 is phosphorylated by Abl kinase, thus suggesting
modulation of macropinocytosis by Abi1–PI-3 kinase complex in
Abl kinase-dependent manner. This hypothesis is consistent with
proposed roles of tyrosine phosphorylation and phospho-inositol
lipid signaling in actin cytoskeleton remodeling. Moreover, our no-
vel data on p85–Abi1 interaction contribute to better understand-
ing of regulatory mechanisms of macropinocytosis and suggest
novel hypotheses regarding its regulation.
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